<DOC>
	<DOCNO>NCT02813967</DOCNO>
	<brief_summary>This randomise , multicenter , phase 3 trial . Patients age 70 year old histologically confirm esophageal cancer randomly assign S-1 concurrent radiotherapy radiotherapy alone.The primary endpoint overall survival .</brief_summary>
	<brief_title>S-1 Concurrent With Radiotherapy Versus Radiotherapy Elderly Patients With Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histological cytologic diagnosis esophageal carcinoma ECOG performance status 01 Age:7085 year Joined study voluntarily sign informed consent form Patients must receive prior anticancer therapy Stage ⅠⅣB（AJCC 2009） Target lesion measure accord RECIST criterion No serious system dysfunction immunodeficiency , Adequate organ function include follow : Hemoglobin ≥9 g/dL , WBC≥3x109/L , Neutrophils ( ANC ) ≥1.5x109/L , platelet count ≥100x 109/L , TBIL &lt; 1.5 x ULN , ALT AST ≦ 2.5 x ULN , creatinine ≦ 1.5 x ULN Multiple carcinoma esophagus , Biopsyproven invasion tracheobronchial tree tracheoesophageal fistula , Metastatic disease ( M1b ) , A primary tumor extend within 2 cm gastroesophageal junction , Prior chemotherapy , prior thoracic radiation , surgical resection primary tumor , history second malignancy nonmelanoma skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>